Arcus Biosciences Quarterly Balance Sheets Chart
Quarterly
|
Annual
Arcus Biosciences Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| assets | ||||||||||||||||||||||||||||||
| current assets: | ||||||||||||||||||||||||||||||
| cash and cash equivalents | 248,000,000 | 192,000,000 | 150,000,000 | 201,000,000 | 156,000,000 | 185,000,000 | 127,000,000 | 184,000,000 | 230,000,000 | 238,000,000 | 206,000,000 | 217,647,000 | 272,629,000 | 548,783,000 | 147,914,000 | 179,432,000 | 320,482,000 | 390,260,000 | 173,415,000 | 221,849,000 | 285,185,000 | 67,326,000 | 57,937,000 | 78,992,000 | 76,068,000 | 68,499,000 | 71,064,000 | 74,889,000 | 169,998,000 | 198,116,000 |
| marketable securities | 663,000,000 | 805,000,000 | 828,000,000 | 888,000,000 | 813,000,000 | 810,000,000 | 632,000,000 | 615,000,000 | 700,000,000 | 716,000,000 | 803,000,000 | |||||||||||||||||||
| receivable from collaboration partners | 15,000,000 | 15,000,000 | 20,000,000 | 16,000,000 | 28,000,000 | 35,000,000 | 38,000,000 | 52,000,000 | 34,000,000 | 33,000,000 | 39,000,000 | 27,286,000 | 35,831,000 | 29,419,000 | 744,595,000 | 871,000 | 1,575,000 | 5,235,000 | 1,049,000 | 2,579,000 | 222,000 | 344,000 | 5,276,000 | |||||||
| prepaid expenses and other current assets | 20,000,000 | 19,000,000 | 18,000,000 | 22,000,000 | 25,000,000 | 34,000,000 | 34,000,000 | 31,000,000 | 22,000,000 | 28,000,000 | 21,625,000 | 15,672,000 | 18,527,000 | 15,620,000 | 17,574,000 | 21,967,000 | 8,680,000 | 5,471,000 | 11,816,000 | 8,665,000 | 8,007,000 | 4,303,000 | 4,223,000 | 3,273,000 | 3,080,000 | 2,321,000 | 2,329,000 | 1,550,000 | 1,834,000 | |
| total current assets | 946,000,000 | 1,031,000,000 | 1,016,000,000 | 1,127,000,000 | 1,022,000,000 | 1,064,000,000 | 831,000,000 | 882,000,000 | 986,000,000 | 1,015,000,000 | 1,067,000,000 | 1,101,116,000 | 1,227,475,000 | 1,264,226,000 | 1,261,750,000 | 545,288,000 | 745,954,000 | 841,870,000 | 735,815,000 | 797,199,000 | 471,599,000 | 166,217,000 | 192,705,000 | 200,488,000 | 227,733,000 | 245,015,000 | 258,948,000 | 265,280,000 | 267,441,000 | 282,068,000 |
| long-term marketable securities | 16,000,000 | 8,000,000 | 14,000,000 | 2,000,000 | 40,000,000 | 100,000,000 | 107,000,000 | 151,000,000 | 80,000,000 | 90,000,000 | 129,000,000 | |||||||||||||||||||
| property and equipment | 44,000,000 | 46,000,000 | 47,000,000 | 48,000,000 | 49,000,000 | 51,000,000 | 51,000,000 | 50,000,000 | 45,000,000 | 37,000,000 | 35,000,000 | 33,892,000 | 33,416,000 | 33,481,000 | 32,455,000 | 28,818,000 | 23,806,000 | 14,849,000 | 10,807,000 | 8,728,000 | 8,264,000 | 8,761,000 | 9,330,000 | 10,011,000 | 10,362,000 | 11,026,000 | 11,107,000 | 11,762,000 | ||
| other noncurrent assets | 69,000,000 | 71,000,000 | 73,000,000 | 75,000,000 | 75,000,000 | 78,000,000 | 106,000,000 | 108,000,000 | 109,000,000 | 112,000,000 | 114,000,000 | |||||||||||||||||||
| total assets | 1,075,000,000 | 1,156,000,000 | 1,150,000,000 | 1,252,000,000 | 1,186,000,000 | 1,293,000,000 | 1,095,000,000 | 1,191,000,000 | 1,220,000,000 | 1,254,000,000 | 1,345,000,000 | 1,393,822,000 | 1,476,773,000 | 1,543,427,000 | 1,591,898,000 | 839,290,000 | 898,773,000 | 935,119,000 | 772,292,000 | 811,075,000 | 481,389,000 | 176,144,000 | 203,110,000 | 216,957,000 | 238,974,000 | 258,530,000 | 274,925,000 | 286,721,000 | 293,865,000 | 305,399,000 |
| liabilities and stockholders' equity | ||||||||||||||||||||||||||||||
| current liabilities: | ||||||||||||||||||||||||||||||
| accounts payable | 29,000,000 | 22,000,000 | 18,000,000 | 13,000,000 | 15,000,000 | 16,000,000 | 17,000,000 | 17,000,000 | 12,000,000 | 28,000,000 | 20,000,000 | 10,546,000 | 21,984,000 | 18,094,000 | 10,261,000 | 13,219,000 | 16,957,000 | 24,544,000 | 15,682,000 | 8,102,000 | 12,052,000 | 2,426,000 | 4,704,000 | 2,905,000 | 2,448,000 | 2,829,000 | 3,102,000 | 2,109,000 | 5,388,000 | 3,920,000 |
| deferred revenue | 71,000,000 | 72,000,000 | 85,000,000 | 105,000,000 | 113,000,000 | 124,000,000 | 91,000,000 | 103,000,000 | 103,000,000 | 97,000,000 | 97,000,000 | |||||||||||||||||||
| other current liabilities | 110,000,000 | 98,000,000 | 123,000,000 | 97,000,000 | 71,000,000 | 64,000,000 | 76,000,000 | 80,000,000 | 65,000,000 | 54,000,000 | 76,000,000 | 2,984,000 | 2,466,000 | 52,000 | 209,000 | 380,000 | 2,381,000 | 3,566,000 | 3,422,000 | 1,463,000 | 1,408,000 | 1,480,000 | 1,490,000 | 1,513,000 | 1,545,000 | 1,560,000 | 1,585,000 | 1,650,000 | 1,732,000 | |
| total current liabilities | 210,000,000 | 192,000,000 | 226,000,000 | 215,000,000 | 199,000,000 | 204,000,000 | 184,000,000 | 200,000,000 | 180,000,000 | 179,000,000 | 193,000,000 | 177,176,000 | 164,024,000 | 161,254,000 | 166,084,000 | 142,866,000 | 130,370,000 | 132,055,000 | 121,669,000 | 162,871,000 | 40,025,000 | 21,004,000 | 22,706,000 | 21,057,000 | 26,513,000 | 19,003,000 | 16,935,000 | 16,611,000 | 16,380,000 | 14,262,000 |
| deferred revenue, noncurrent | 60,000,000 | 219,000,000 | 234,000,000 | 289,000,000 | 214,000,000 | 242,000,000 | 307,000,000 | 326,000,000 | 330,000,000 | 330,000,000 | 355,000,000 | 382,584,000 | 429,339,000 | 456,905,000 | 462,217,000 | 94,675,000 | 103,908,000 | 113,369,000 | 122,830,000 | 91,298,000 | 8,522,000 | 10,272,000 | 12,022,000 | 13,772,000 | 10,522,000 | 12,272,000 | 16,984,000 | 18,546,000 | 16,087,000 | 17,337,000 |
| long-term debt | 97,000,000 | 48,000,000 | 48,000,000 | 47,000,000 | ||||||||||||||||||||||||||
| other noncurrent liabilities | 159,000,000 | 166,000,000 | 157,000,000 | 136,000,000 | 138,000,000 | 140,000,000 | 142,000,000 | 145,000,000 | 144,000,000 | 145,000,000 | 140,000,000 | |||||||||||||||||||
| commitments | ||||||||||||||||||||||||||||||
| stockholders’ equity: | ||||||||||||||||||||||||||||||
| common stock and additional paid-in capital: 0.0001 par value per share; 400.0 shares authorized; 106.4 shares in 2025 and 92.2 shares in 2024 issued and outstanding | 1,793,000,000 | |||||||||||||||||||||||||||||
| accumulated deficit | -1,244,000,000 | -1,244,000,000 | -1,132,000,000 | -1,038,000,000 | -946,000,000 | -853,000,000 | -849,000,000 | -768,000,000 | -697,000,000 | -622,000,000 | -542,000,000 | -474,898,000 | -409,979,000 | -343,347,000 | -275,354,000 | -554,722,000 | -476,747,000 | -400,777,000 | -328,184,000 | -276,331,000 | -278,153,000 | -233,079,000 | -205,326,000 | -188,728,000 | -166,376,000 | -138,286,000 | -122,828,000 | -110,533,000 | -99,722,000 | -86,188,000 |
| total stockholders’ equity | 549,000,000 | 531,000,000 | 485,000,000 | 565,000,000 | 635,000,000 | 707,000,000 | 462,000,000 | 520,000,000 | 566,000,000 | 600,000,000 | 657,000,000 | 698,701,000 | 747,386,000 | 796,579,000 | 841,450,000 | 542,607,000 | 604,555,000 | 664,790,000 | 502,304,000 | 544,417,000 | 428,710,000 | 140,638,000 | 163,842,000 | 177,227,000 | 196,646,000 | 221,567,000 | 234,942,000 | 245,121,000 | 254,574,000 | 266,591,000 |
| total liabilities and stockholders’ equity | 1,075,000,000 | 1,156,000,000 | 1,150,000,000 | 1,252,000,000 | 1,186,000,000 | 1,293,000,000 | 1,095,000,000 | 1,191,000,000 | 1,220,000,000 | 1,254,000,000 | 1,345,000,000 | 1,393,822,000 | 1,476,773,000 | 1,543,427,000 | 1,591,898,000 | 839,290,000 | 898,773,000 | 935,119,000 | 772,292,000 | 811,075,000 | 481,389,000 | 203,110,000 | ||||||||
| common stock and additional paid-in capital: 0.0001 par value per share; 400.0 shares authorized; 105.9 shares in 2025 and 92.2 shares in 2024 issued and outstanding | 1,775,000,000 | |||||||||||||||||||||||||||||
| common stock and additional paid-in capital: 0.0001 par value per share; 400.0 shares authorized; 92.2 shares in 2024 and 75.5 shares in 2023 issued and outstanding | 1,617,000,000 | |||||||||||||||||||||||||||||
| common stock and additional paid-in capital: 0.0001 par value per share; 400.0 shares authorized; 91.5 shares in 2024 and 75.5 shares in 2023 issued and outstanding | 1,602,000,000 | |||||||||||||||||||||||||||||
| accumulated other comprehensive loss | 1,000,000 | -1,000,000 | -1,000,000 | -3,000,000 | -4,000,000 | -4,000,000 | -7,000,000 | -9,801,000 | -7,244,000 | -4,660,000 | -107,000 | -108,000 | -83,000 | -97,000 | ||||||||||||||||
| common stock and additional paid-in capital: 0.0001 par value per share; 400.0 shares authorized; 91.3 shares in 2024 and 75.5 shares in 2023 issued and outstanding | 1,582,000,000 | |||||||||||||||||||||||||||||
| common stock and additional paid-in capital: 0.0001 par value per share; 400.0 shares authorized; 90.9 shares in 2024 and 75.5 shares in 2023 issued and outstanding | 1,561,000,000 | |||||||||||||||||||||||||||||
| common stock and additional paid-in capital: 0.0001 par value per share; 400.0 shares authorized; 75.5 shares in 2023 and 72.9 shares in 2022 issued and outstanding | 1,311,000,000 | |||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value per share; 10.0 shares authorized; no shares issued and outstanding. | ||||||||||||||||||||||||||||||
| common stock and additional paid-in capital: 0.0001 par value per share; 400.0 shares authorized; 74.8 shares in 2023 and 72.9 shares in 2022 issued and outstanding | 1,291,000,000 | |||||||||||||||||||||||||||||
| common stock and additional paid-in capital: 0.0001 par value per share; 400.0 shares authorized; 74.5 shares in 2023 and 72.9 shares in 2022 issued and outstanding | 1,267,000,000 | |||||||||||||||||||||||||||||
| common stock and additional paid-in capital: 0.0001 par value per share; 400.0 shares authorized; 73.1 shares in 2023 and 72.9 shares in 2022 issued and outstanding | 1,226,000,000 | |||||||||||||||||||||||||||||
| prepaid and other current assets | 19,000,000 | |||||||||||||||||||||||||||||
| preferred stock: 0.0001 par value per share; 10.0 shares authorized; no shares issued and outstanding | ||||||||||||||||||||||||||||||
| common stock and additional paid-in capital: 0.0001 par value per share; 400.0 shares authorized; 72.9 shares in 2022 and 70.8 shares in 2021 issued and outstanding | 1,206,000,000 | |||||||||||||||||||||||||||||
| short-term investments | 831,135,000 | 900,147,000 | 664,751,000 | 351,394,000 | 345,210,000 | 400,530,000 | 436,666,000 | 555,231,000 | 560,583,000 | 177,288,000 | 90,540,000 | 130,333,000 | 111,997,000 | 148,330,000 | 173,436,000 | 185,480,000 | 182,948,000 | 95,700,000 | 82,064,000 | |||||||||||
| accrued interest receivable | 3,423,000 | 3,196,000 | 2,746,000 | 2,227,000 | 2,201,000 | 1,400,000 | 1,029,000 | 649,000 | 372,000 | 239,000 | ||||||||||||||||||||
| long-term investments | 143,138,000 | 98,329,000 | 128,836,000 | 181,990,000 | 218,730,000 | 84,096,000 | 57,986,000 | 6,440,000 | 2,700,000 | 5,992,000 | 1,201,000 | 3,181,000 | 7,746,000 | 11,792,000 | 10,595,000 | |||||||||||||||
| right-of-use assets | 102,073,000 | 104,025,000 | 102,992,000 | 104,968,000 | 35,553,000 | 36,137,000 | 12,243,000 | 12,781,000 | ||||||||||||||||||||||
| restricted cash | 3,005,000 | 3,005,000 | 3,005,000 | 3,005,000 | 3,005,000 | 3,005,000 | 1,988,000 | 203,000 | 203,000 | 203,000 | 203,000 | 203,000 | 203,000 | 203,000 | 203,000 | 203,000 | 203,000 | 203,000 | 203,000 | |||||||||||
| other long-term assets | 10,598,000 | 10,523,000 | 10,887,000 | 7,730,000 | 7,896,000 | 5,775,000 | 6,183,000 | 6,246,000 | 2,245,000 | 1,323,000 | 963,000 | 872,000 | 263,000 | 319,000 | 315,000 | 284,000 | 205,000 | 205,000 | 205,000 | |||||||||||
| accrued research and development | 39,827,000 | 35,019,000 | 37,654,000 | 29,587,000 | 40,470,000 | |||||||||||||||||||||||||
| other accrued liabilities | 20,528,000 | 14,438,000 | 16,196,000 | 24,181,000 | 14,625,000 | 9,706,000 | 7,536,000 | 9,543,000 | 7,496,000 | 5,611,000 | ||||||||||||||||||||
| deferred revenue, current | 103,291,000 | 90,117,000 | 89,310,000 | 102,003,000 | 74,343,000 | 74,571,000 | 74,571,000 | 74,571,000 | 115,614,000 | 7,000,000 | 7,000,000 | 7,000,000 | 7,000,000 | 7,000,000 | 7,000,000 | 6,250,000 | 6,250,000 | 5,000,000 | 5,000,000 | |||||||||||
| operating lease liabilities, noncurrent | 119,195,000 | 121,343,000 | 114,815,000 | 116,887,000 | 48,943,000 | 49,741,000 | 14,706,000 | 15,243,000 | ||||||||||||||||||||||
| other long-term liabilities | 16,166,000 | 14,681,000 | 13,874,000 | 5,260,000 | 10,199,000 | 10,199,000 | 10,199,000 | 10,246,000 | 8,178,000 | 693,000 | 640,000 | 806,000 | 1,026,000 | 1,283,000 | 1,543,000 | 1,792,000 | 2,047,000 | 2,308,000 | 2,554,000 | |||||||||||
| total liabilities | 695,121,000 | 729,387,000 | 746,848,000 | 750,448,000 | 296,683,000 | 294,218,000 | 270,329,000 | 269,988,000 | 266,658,000 | 52,679,000 | 35,506,000 | 39,268,000 | 39,730,000 | 42,328,000 | 36,963,000 | 39,983,000 | 41,600,000 | 39,291,000 | 38,808,000 | |||||||||||
| preferred stock, 0.0001 par value, 10,000,000 shares authorized; no shares issued and outstanding. | ||||||||||||||||||||||||||||||
| common stock | 7,000 | 7,000 | 7,000 | 7,000 | 7,000 | 7,000 | 7,000 | 6,000 | 6,000 | 6,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | |||||||||||||
| additional paid-in capital | 1,183,393,000 | 1,164,602,000 | 1,144,579,000 | 1,118,058,000 | 1,097,414,000 | 1,081,341,000 | 1,065,562,000 | 830,438,000 | 820,661,000 | 706,713,000 | 373,425,000 | 369,100,000 | 365,898,000 | 362,905,000 | 359,820,000 | 357,873,000 | 355,758,000 | 354,375,000 | 352,872,000 | |||||||||||
| preferred stock, 0.0001 par value, 10,000,000 shares authorized as of june 30, 2022 and december 31, 2021; no shares issued and outstanding as of june 30, 2022 and december 31, 2021 | ||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value, 10,000,000 shares authorized as of march 31, 2022 and december 31, 2021; no shares issued and outstanding as of march 31, 2022 and december 31, 2021 | ||||||||||||||||||||||||||||||
| liabilities | ||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value, 10,000,000 shares authorized as of december 31, 2021 and 2020; no shares issued and outstanding as of december 31, 2021 and 2020 | ||||||||||||||||||||||||||||||
| accumulated other comprehensive income | -1,261,000 | -92,000 | -46,000 | -2,000 | 44,000 | 81,000 | 144,000 | 288,000 | 64,000 | 53,000 | 113,000 | 29,000 | ||||||||||||||||||
| preferred stock, 0.0001 par value, 10,000,000 shares authorized as of september 30, 2021 and december 31, 2020; no shares issued and outstanding as of september 30, 2021 and december 31, 2020 | ||||||||||||||||||||||||||||||
| accrued research and development expenses | 28,756,000 | 23,023,000 | 18,307,000 | 28,237,000 | 13,899,000 | |||||||||||||||||||||||||
| preferred stock, 0.0001 par value, 10,000,000 shares authorized as of june 30, 2021 and december 31, 2020; no shares issued and outstanding as of june 30, 2021 and december 31, 2020 | ||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value, 10,000,000 shares authorized as of march 31, 2021 and december 31, 2020; no shares issued and outstanding as of march 31, 2021 and december 31, 2020 | ||||||||||||||||||||||||||||||
| deferred rent, non-current | ||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value, 10,000,000 shares authorized as of december 31, 2020 and 2019; no shares issued and outstanding as of december 31, 2020 and 2019 | ||||||||||||||||||||||||||||||
| current liabilities | ||||||||||||||||||||||||||||||
| deferred rent, noncurrent | 4,311,000 | |||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value, 10,000,000 shares authorized as of september 30, 2020 and december 31, 2019; no shares issued and outstanding as of september 30, 2020 and december 31, 2019 | ||||||||||||||||||||||||||||||
| deferred rent | 3,439,000 | 3,590,000 | 3,734,000 | 3,875,000 | 4,010,000 | 4,145,000 | 4,272,000 | 4,396,000 | 4,516,000 | 4,655,000 | ||||||||||||||||||||
| preferred stock, 0.0001 par value, 10,000,000 shares authorized as of june 30, 2020 and december 31, 2019; no shares issued and outstanding as of june 30, 2020 and december 31, 2019 | ||||||||||||||||||||||||||||||
| accrued liabilities | 10,170,000 | 9,522,000 | 9,662,000 | 15,552,000 | 7,629,000 | 6,023,000 | 6,667,000 | 4,342,000 | 3,610,000 | |||||||||||||||||||||
| preferred stock, 0.0001 par value, 10,000,000 shares authorized as of march 31, 2020 and december 31, 2019; no shares issued and outstanding as of march 31, 2020 and december 31, 2019 | ||||||||||||||||||||||||||||||
| total liabilities, convertible preferred stock and stockholders’ equity | 176,144,000 | 216,957,000 | 238,974,000 | 258,530,000 | 274,925,000 | 286,721,000 | 293,865,000 | 305,399,000 | ||||||||||||||||||||||
| receivable from collaboration partner | 132,000 | 5,000,000 | ||||||||||||||||||||||||||||
| amounts owed by a related party | 62,000 | 83,000 | 114,000 | 193,000 | 54,000 | |||||||||||||||||||||||||
| equity investment in related party | 357,000 | 770,000 | 1,202,000 | 1,525,000 | 1,711,000 | 515,000 | ||||||||||||||||||||||||
| preferred stock, 0.0001 par value, 10,000,000 shares authorized as of december 31, 2019 and 2018; no shares issued and outstanding as of december 31, 2019 and 2018 | ||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value, 10,000,000 shares authorized as of september 30, 2019 and december 31, 2018; no shares issued and outstanding as of september 30, 2019 and december 31, 2018 | ||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value, 10,000,000 shares authorized as of june 30, 2019 and december 31, 2018; no shares issued and outstanding as of june 30, 2019 and december 31, 2018 | ||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value, 10,000,000 shares authorized as of march 31, 2019 and december 31, 2018; no shares issued and outstanding as of march 31, 2019 and december 31, 2018 | ||||||||||||||||||||||||||||||
| convertible preferred stock | ||||||||||||||||||||||||||||||
| stockholders’ equity | ||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value, 10,000,000 shares authorized as of december 31, 2018; no shares issued and outstanding | ||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value, 10,000,000 shares and no shares authorized as of september 30, 2018 and december 31, 2017, respectively; no shares issued and outstanding as of september 30, 2018 and december 31, 2017, respectively | ||||||||||||||||||||||||||||||
| property, plant and equipment-net | 12,513,000 | 11,813,000 | ||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value, 10,000,000 shares and no shares authorized as of june 30, 2018 and december 31, 2017, respectively; no shares issued and outstanding as of june 30, 2018 and december 31, 2017, respectively | ||||||||||||||||||||||||||||||
| common stock; 0.0001 par value; 400,000,000 and 153,993,227 shares authorized as of june 30, 2018 and december 31, 2017, respectively; 44,456,659 and 4,090,898 shares issued and outstanding as of june 30, 2018 and december 31, 2017 respectively | 4,000 | |||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value, 10,000,000 shares and no shares authorized as of march 31, 2018 and december 31, 2017, respectively; no shares issued and outstanding as of march 31, 2018 and december 31, 2017, respectively | ||||||||||||||||||||||||||||||
| common stock; 0.0001 par value; 400,000,000 and 153,993,227 shares authorized as of march 31, 2018 and december 31, 2017, respectively; 44,454,275 and 4,090,898 shares issued and outstanding as of march 31, 2018 and december 31, 2017 respectively | 4,000 |
We provide you with 20 years of balance sheets for Arcus Biosciences stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Arcus Biosciences. Explore the full financial landscape of Arcus Biosciences stock with our expertly curated balance sheets.
The information provided in this report about Arcus Biosciences stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.